Cyclacel Pharmaceuticals
CYCC
Market cap $46.9M

0.2261 USD

+0.0097

4.48%

At close Apr 17, 4:00 PM EDT

After hours

0.2111

-0.0150

6.63%

1 day

4.48%

5 days

-1.27%

1 month

-25.82%

3 months

-36.47%

6 months

-77.61%

Year to date

-39.04%

1 year

-88.46%

5 years

-99.76%

10 years

-99.99%

About: Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Employees: 12

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

50% more capital invested

Capital invested by funds: $200K [Q3] → $300K (+$100K) [Q4]

29% more funds holding

Funds holding: 14 [Q3] → 18 (+4) [Q4]

1.0% more ownership

Funds ownership: 10.27% [Q3] → 11.27% (+1.0%) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CYCC.

See Analyst Rankings

Financial journalist opinion

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025.

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Zacks Investment Research

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update.

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq's minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule").

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

See News Rankings

Charts implemented using Lightweight Charts™